Journal
Future Oncology
Publication Date
4-1-2025
Volume
21
Issue
8
First Page
943
Last Page
951
Document Type
Open Access Publication
DOI
10.1080/14796694.2025.2463798
Rights and Permissions
Cote GM, Chawla SP, Demetri G, Kasper B, Jones RL, Broto JM, Wooley J, Weiss MC, Tafuto S, Badalamenti G, Carrasco I, Peinado P, Blay JY, Boggio G, Fernandez C, Nieto A, Kahatt C, Alfaro V, Le Cesne A. SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncol. 2025 Apr;21(8):943-951. doi: 10.1080/14796694.2025.2463798. © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Recommended Citation
Cote, Gregory M; Weiss, Mia C; and et al., "SaLuDo: A randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma." Future Oncology. 21, 8. 943 - 951. (2025).
https://digitalcommons.wustl.edu/oa_4/4911
Department
ICTS (Institute of Clinical and Translational Sciences)
